For women with breast cancer who take adjuvant Tamoxifen daily for 5 years, their risk of dying from the disease drops by one third, compared to their chances without the drug, researchers reported in The Lancet today. They referred specifically to women with estrogen-receptor positive breast cancer, also known as hormone-sensitive breast cancer...
More...
Hybrid Mode
